SG11201907594TA - Methods of treating cancer with farnesyltransferase inhibitors - Google Patents
Methods of treating cancer with farnesyltransferase inhibitorsInfo
- Publication number
- SG11201907594TA SG11201907594TA SG11201907594TA SG11201907594TA SG11201907594TA SG 11201907594T A SG11201907594T A SG 11201907594TA SG 11201907594T A SG11201907594T A SG 11201907594TA SG 11201907594T A SG11201907594T A SG 11201907594TA SG 11201907594T A SG11201907594T A SG 11201907594TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- methods
- treating cancer
- english
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) o mum I E l° OM 101 1001101 110111110 011 (10) International Publication Number WO 2018/156609 Al WIPO I PCT (51) International Patent Classification: A61K 31/4709 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/018989 (22) International Filing Date: 21 February 2018 (21.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/461,602 21 February 2017 (21.02.2017) US 62/507,749 17 May 2017 (17.05.2017) US 62/519,819 14 June 2017 (14.06.2017) US 15/820,157 21 November 2017 (21.11.2017) US 15/820,012 21 November 2017 (21.11.2017) US 62/596,653 08 December 2017 (08.12.2017) US (71) Applicant: KURA ONCOLOGY, INC. [US/US]; 3033 Science Park Road, Suite 220, San Diego, CA 92121 (US). (72) Inventors: GUALBERTO, Antonio; 8 Larch Road, Ac- ton, MA 01720 (US). SCHOLZ, Catherine, Rose; 1 Nashua Street, Woburn, MA 01801 (US). (74) Agent: RIEGER, Dale, L. et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (54) Title: METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS 4 - 5 - 6 - 7 - 8 - 1 Cl) 18 - 01 1 3 6 10 C:0) Cycles FIG. 1 kr) (57) : The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (\"PTCL\"), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject C:0) is likely to be responsive to the FTI treatment based on gene expression characteristics. o [Continued on next page] WO 2018/156609 Al MIDEDIMOMMIDIREEMOMOHEMICHINVOIS MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461602P | 2017-02-21 | 2017-02-21 | |
| US201762507749P | 2017-05-17 | 2017-05-17 | |
| US201762519819P | 2017-06-14 | 2017-06-14 | |
| US15/820,157 US9956215B1 (en) | 2017-02-21 | 2017-11-21 | Methods of treating cancer with farnesyltransferase inhibitors |
| US15/820,012 US10137121B2 (en) | 2017-02-21 | 2017-11-21 | Methods of treating cancer with farnesyltransferase inhibitors |
| US201762596653P | 2017-12-08 | 2017-12-08 | |
| PCT/US2018/018989 WO2018156609A1 (en) | 2017-02-21 | 2018-02-21 | Methods of treating cancer with farnesyltransferase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907594TA true SG11201907594TA (en) | 2019-09-27 |
Family
ID=63253363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907594TA SG11201907594TA (en) | 2017-02-21 | 2018-02-21 | Methods of treating cancer with farnesyltransferase inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| EP (3) | EP3542800B1 (en) |
| JP (1) | JP7289795B2 (en) |
| KR (3) | KR20200090982A (en) |
| CN (4) | CN114796218A (en) |
| AU (3) | AU2018225566B2 (en) |
| BR (1) | BR112019017375A2 (en) |
| CA (1) | CA3053795A1 (en) |
| ES (2) | ES2927228T3 (en) |
| IL (1) | IL268722A (en) |
| MX (2) | MX2019009821A (en) |
| PH (1) | PH12019501918A1 (en) |
| SG (1) | SG11201907594TA (en) |
| TW (3) | TWI663974B (en) |
| WO (1) | WO2018156609A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9956215B1 (en) | 2017-02-21 | 2018-05-01 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
| US20220143006A1 (en) * | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| ES8702440A1 (en) | 1984-10-04 | 1986-12-16 | Monsanto Co | Prolonged release of biologically active somatotropins. |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5561058A (en) | 1986-08-22 | 1996-10-01 | Hoffmann-La Roche Inc. | Methods for coupled high temperatures reverse transcription and polymerase chain reactions |
| US5693517A (en) | 1987-06-17 | 1997-12-02 | Roche Molecular Systems, Inc. | Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions |
| US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| CA1340843C (en) | 1987-07-31 | 1999-12-07 | J. Lawrence Burg | Selective amplification of target polynucleotide sequences |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| ZA918965B (en) | 1990-11-13 | 1992-08-26 | Siska Diagnostics Inc | Nucleic acid amplification by two-enzyme,self-sustained sequence replication |
| US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| ES2161715T3 (en) | 1992-03-04 | 2001-12-16 | Univ California | COMPARATIVE GENOMIC HYBRIDIZATION (HGC). |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
| US5491063A (en) | 1994-09-01 | 1996-02-13 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
| US5571673A (en) | 1994-11-23 | 1996-11-05 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (en) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | Delayed release microsphere of drug |
| US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (en) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | PREPARATION OF MAINTENANCE RELEASE. |
| US6197350B1 (en) | 1996-12-20 | 2001-03-06 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| ATE252104T1 (en) | 1996-12-20 | 2003-11-15 | Tovarischestvo S Ogranichennoi | METHOD AND APPARATUS FOR PRODUCING 1SS, 10SS-EPOXY-13-DIMETHYLAMINO-GUAIA-3(4)-EN-6,12-LID-HYDROCHLORIDE |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| IL136951A0 (en) | 1998-01-16 | 2001-06-14 | Takeda Chemical Industries Ltd | Sustained-release composition, method of its production and use thereof |
| JP4022044B2 (en) | 1998-03-05 | 2007-12-12 | フォーミュラ ワン アドミニストレイション リミテッド | Data communication system |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (en) | 1998-05-16 | 1999-12-06 | 허영섭 | Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof |
| AU5086499A (en) | 1998-07-01 | 2000-01-24 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
| WO2000001411A1 (en) | 1998-07-06 | 2000-01-13 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties |
| ATE321037T1 (en) | 1998-08-27 | 2006-04-15 | Pfizer Prod Inc | ALKINYL SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USABLE AS ANTICANCER AGENTS |
| EP1107962B1 (en) | 1998-08-27 | 2005-02-23 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
| US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| AU3074001A (en) | 1999-12-09 | 2001-06-18 | Advanced Research And Technology Institute, Inc. | Fluorescent in situ rt-pcr |
| US6838467B2 (en) | 2000-02-24 | 2005-01-04 | Janssen Pharmaceutica N. V. | Dosing regimen |
| WO2002070751A1 (en) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pcr method |
| US7122799B2 (en) | 2003-12-18 | 2006-10-17 | Palo Alto Research Center Incorporated | LED or laser enabled real-time PCR system and spectrophotometer |
| WO2006036892A2 (en) * | 2004-09-24 | 2006-04-06 | Sapphire Therapeutics, Inc. | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| ATE475408T1 (en) * | 2005-10-14 | 2010-08-15 | Janssen Pharmaceutica Nv | FORMULATIONS OF TIPIFARNIB FOR INTRAVENOUS ADMINISTRATION |
| US8603477B2 (en) * | 2008-10-31 | 2013-12-10 | Abbvie Biotherapeutics Inc. | Use of anti-CS1 antibodies for treatment of rare lymphomas |
| US20110281814A1 (en) * | 2009-01-30 | 2011-11-17 | Genzyme Corporation | Methods and compositions for treating breast cancer |
| JP6034784B2 (en) * | 2010-07-28 | 2016-11-30 | ジャンセン ダイアグノスティックス，エルエルシー | Method for determining an acute leukemia response to treatment with a farnesyltransferase inhibitor |
| EP2476441A1 (en) * | 2011-01-13 | 2012-07-18 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells |
| BR112014011144A2 (en) * | 2011-11-09 | 2017-05-16 | Bristol Myers Squibb Co | treatment of hematological malignancies with an anti-cxcr4 antibody |
| CN103787907B (en) * | 2014-02-17 | 2015-05-27 | 华东理工大学 | Aniline compound as farnesyltransferase inhibitor and application thereof |
| US20190119758A1 (en) * | 2016-04-22 | 2019-04-25 | Kura Oncology, Inc. | Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors |
-
2018
- 2018-02-21 AU AU2018225566A patent/AU2018225566B2/en active Active
- 2018-02-21 TW TW107105861A patent/TWI663974B/en not_active IP Right Cessation
- 2018-02-21 KR KR1020207021424A patent/KR20200090982A/en not_active Application Discontinuation
- 2018-02-21 JP JP2019566054A patent/JP7289795B2/en active Active
- 2018-02-21 WO PCT/US2018/018989 patent/WO2018156609A1/en active Application Filing
- 2018-02-21 TW TW108113624A patent/TWI693074B/en active
- 2018-02-21 CN CN202210399515.8A patent/CN114796218A/en active Pending
- 2018-02-21 ES ES19172562T patent/ES2927228T3/en active Active
- 2018-02-21 TW TW109114622A patent/TWI738314B/en active
- 2018-02-21 BR BR112019017375-7A patent/BR112019017375A2/en not_active Application Discontinuation
- 2018-02-21 CN CN201880002051.4A patent/CN109475550A/en active Pending
- 2018-02-21 CN CN201910346412.3A patent/CN109999037A/en active Pending
- 2018-02-21 MX MX2019009821A patent/MX2019009821A/en unknown
- 2018-02-21 SG SG11201907594TA patent/SG11201907594TA/en unknown
- 2018-02-21 CA CA3053795A patent/CA3053795A1/en active Pending
- 2018-02-21 EP EP19172562.1A patent/EP3542800B1/en active Active
- 2018-02-21 CN CN202210399518.1A patent/CN114712354A/en active Pending
- 2018-02-21 KR KR1020187032097A patent/KR102003179B1/en active IP Right Grant
- 2018-02-21 ES ES18708563T patent/ES2892157T3/en active Active
- 2018-02-21 EP EP18708563.4A patent/EP3432883B1/en active Active
- 2018-02-21 KR KR1020197020747A patent/KR102138904B1/en active IP Right Grant
- 2018-02-21 EP EP22176008.5A patent/EP4119142A1/en not_active Withdrawn
-
2019
- 2019-05-21 AU AU2019203548A patent/AU2019203548C1/en active Active
- 2019-08-15 IL IL26872219A patent/IL268722A/en unknown
- 2019-08-16 MX MX2022008843A patent/MX2022008843A/en unknown
- 2019-08-19 PH PH12019501918A patent/PH12019501918A1/en unknown
- 2019-10-11 AU AU2019246922A patent/AU2019246922A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
| SG11201903786UA (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201907948TA (en) | Formulations comprising pd-1 binding proteins and methods of making thereof | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |